Cargando…
Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study
BACKGROUND: Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few predictors of early HCC progression and limited strategies to prevent progression in patients with HBV-related cirrhosis who receive nucleos(t)ide analog...
Autores principales: | Yang, Dan-Hong, Wang, Wei-Ping, Zhang, Qiang, Pan, Hong-Ying, Huang, Yi-Cheng, Zhang, Jia-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108039/ https://www.ncbi.nlm.nih.gov/pubmed/34007137 http://dx.doi.org/10.3748/wjg.v27.i17.2025 |
Ejemplares similares
-
Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis
por: Liu, Dong, et al.
Publicado: (2022) -
Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study
por: Appel-da-Silva, Marcelo Campos, et al.
Publicado: (2016) -
Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis
por: Yao, Xin, et al.
Publicado: (2021) -
Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt
por: Yao, Xin, et al.
Publicado: (2021) -
Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis
por: Li, Man-Yu, et al.
Publicado: (2023)